Last 7 days
-0.7%
Last 30 days
-0.2%
Last 90 days
-10.5%
Trailing 12 Months
-6.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 441.4B | 324.2B | -0.20% | -6.09% | 21.94 | 1.36 | 12.71% | 16.40% |
CI | 91.1B | 180.5B | -11.13% | 8.36% | 13.64 | 1.92 | 3.70% | 24.58% |
HUM | 61.5B | 92.9B | -2.15% | 11.75% | 21.9 | 0.66 | 11.81% | -4.33% |
CNC | 34.8B | 144.5B | -7.74% | -24.92% | 28.96 | 0.24 | 14.74% | -10.76% |
MID-CAP | ||||||||
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
HQY | 5.0B | 831.2M | -10.22% | -12.94% | -84.58 | 5.98 | 12.11% | -862.52% |
AMN | 3.5B | 5.2B | -7.83% | -20.48% | 7.82 | 0.66 | 31.60% | 35.63% |
CRVL | 3.3B | 704.5M | 3.42% | 12.97% | 48.19 | 4.64 | 13.56% | 10.15% |
PDCO | 2.6B | 6.4B | -0.93% | -15.13% | 13.37 | 0.41 | -0.52% | 17.01% |
SMALL-CAP | ||||||||
ADUS | 1.7B | 951.1M | -0.43% | 14.44% | 37.41 | 1.81 | 10.02% | 1.99% |
TVTY | 1.6B | - | 0.59% | 17.88% | 18.77 | 3.24 | - | - |
RDNT | 1.3B | 1.4B | 7.33% | 11.89% | 125.85 | 0.94 | 8.74% | -56.93% |
BKD | 552.4M | 2.8B | -7.81% | -58.16% | -2.32 | 0.2 | 2.43% | -140.13% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 2.9% | 324,162 | 315,118 | 306,561 | 297,550 | 287,597 |
S&GA Expenses | 3.8% | 47,782 | 46,045 | 45,107 | 43,757 | 42,579 |
Costs and Expenses | 2.7% | 295,727 | 288,033 | 281,226 | 273,369 | 263,627 |
EBITDA | 5.2% | 31,835 | 30,274 | 28,492 | 27,314 | - |
EBITDA Margin | 2.2% | 0.10* | 0.10* | 0.12* | 0.09* | - |
Earnings Before Taxes | 4.4% | 26,343 | 25,238 | 23,582 | 22,485 | 22,310 |
EBT Margin | 1.5% | 0.08* | 0.08* | 0.10* | 0.08* | - |
Interest Expenses | 13.3% | 2,092 | 1,847 | 1,753 | 1,696 | 1,660 |
Net Income | 3.6% | 20,120 | 19,430 | 18,254 | 17,450 | 17,285 |
Net Income Margin | 0.7% | 0.06* | 0.06* | 0.07* | 0.06* | - |
Free Cahsflow | -25.3% | 23,404 | 31,326 | 20,452 | 19,216 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.1% | 245,705 | 243,064 | 230,172 | 221,238 | 212,206 |
Current Assets | -16.7% | 69,069 | 82,937 | 68,356 | 69,029 | 61,758 |
Cash Equivalents | -39.9% | 23,365 | 38,845 | 24,612 | 25,482 | 21,375 |
Net PPE | 7.0% | 10,128 | 9,469 | 9,421 | 9,183 | 8,969 |
Goodwill | 11.3% | 93,352 | 83,904 | 84,159 | 77,548 | 75,795 |
Liabilities | -0.5% | 159,358 | 160,143 | 149,045 | 143,591 | 135,727 |
Current Liabilities | -11.6% | 89,237 | 100,935 | 88,698 | 88,170 | 78,292 |
LT Debt, Current | - | 3,620 | - | - | - | - |
LT Debt, Non Current | 20.0% | 54,513 | 45,438 | 45,799 | 40,796 | 42,383 |
Shareholder's Equity | 4.3% | 81,450 | 78,064 | 76,205 | 76,128 | 75,045 |
Retained Earnings | 2.9% | 86,156 | 83,722 | 80,540 | 78,782 | 77,134 |
Additional Paid-In Capital | - | - | - | - | - | - |
Accumulated Depreciation | 15.7% | 6,930 | 5,992 | - | - | - |
Shares Outstanding | -0.1% | 934 | 935 | 935 | 939 | 941 |
Minority Interest | 7.6% | 3,678 | 3,418 | 3,385 | 3,362 | 3,285 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -22.8% | 26,206 | 33,957 | 22,988 | 21,657 | 22,343 |
Share Based Compensation | 4.6% | 925 | 884 | 878 | 843 | 800 |
Cashflow From Investing | -129.8% | -28,476 | -12,391 | -13,423 | -10,338 | -10,372 |
Cashflow From Financing | 211.4% | 4,226 | -3,793 | -4,774 | -5,938 | -7,455 |
Dividend Payments | 13.5% | 5,991 | 5,280 | - | - | - |
Buy Backs | -0.7% | 7,000 | 7,050 | 7,100 | 5,850 | 5,000 |
31.9%
18.5%
0%
Y-axis is the maximum loss one would have experienced if UnitedHealth Group was unfortunately bought at previous high price.
24.5%
22.1%
18.9%
25.5%
FIve years rolling returns for UnitedHealth Group.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-30 | REFRAME WEALTH, LLC | new | - | 217,374 | 217,374 | 0.08% |
2023-03-30 | LUTS & GREENLEIGH GROUP, INC | new | - | 584,777 | 584,777 | 0.74% |
2023-03-28 | Acrisure Capital Management, LLC | new | - | 350,449 | 350,449 | 0.39% |
2023-03-28 | Werba Rubin Papier Wealth Management | new | - | 205,485 | 205,485 | 0.09% |
2023-03-28 | Prostatis Group LLC | unchanged | - | 13,575 | 286,297 | 0.17% |
2023-03-24 | Longbow Finance SA | new | - | 23,176,800 | 23,176,800 | 3.12% |
2023-03-23 | MetLife Investment Management, LLC | reduced | -2.00 | 4,115,630 | 147,366,000 | 1.18% |
2023-03-22 | Pictet North America Advisors SA | reduced | -4.56 | 65,648 | 35,339,100 | 6.08% |
2023-03-22 | Campion Asset Management | unchanged | - | 47,437 | 991,437 | 0.97% |
2023-03-17 | American Portfolios Advisors | added | 18.78 | 2,222,960 | 15,459,000 | 0.66% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 9.00% | 84,052,380 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.0% | 74,418,906 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.44% | 79,483,862 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.4% | 69,275,884 | SC 13G/A | |
Feb 16, 2021 | capital world investors | 3.7% | 35,185,176 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.34% | 79,092,547 | SC 13G/A | |
Feb 08, 2021 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2021 | blackrock inc. | 7.5% | 71,592,885 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 345.86 -26.82% | 428.66 -9.30% | 581.58 23.06% | 751.27 58.97% | 886.42 87.57% |
Current Inflation | 316.31 -33.07% | 386.18 -18.28% | 513.45 8.65% | 654.15 38.42% | 765.82 62.05% |
Very High Inflation | 280.11 -40.73% | 335.19 -29.07% | 433.69 -8.23% | 542.29 14.75% | 628.11 32.91% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 28, 2023 | 8-K | Current Report | |
Mar 24, 2023 | 424B5 | Prospectus Filed | |
Mar 24, 2023 | FWP | Prospectus Filed | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 23, 2023 | 424B5 | Prospectus Filed | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 23, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-21 | Gil Kristen | acquired | - | - | 1.00 | - |
2023-03-21 | MCNABB FREDERICK WILLIAM III | acquired | - | - | 19.00 | - |
2023-03-21 | McSweeney Erin | acquired | - | - | 24.144 | evp chief people officer |
2023-03-21 | McMahon Dirk C | acquired | - | - | 62.496 | pres. & coo, uhg & ceo, uhc |
2023-03-21 | ROOS THOMAS E | acquired | - | - | 18.073 | chief accounting officer |
2023-03-21 | GARCIA PAUL R | acquired | - | - | 2.00 | - |
2023-03-21 | Noseworthy John H | acquired | - | - | 14.00 | - |
2023-03-21 | FLYNN TIMOTHY PATRICK | acquired | - | - | 25.00 | - |
2023-03-21 | Bondy Rupert M | acquired | - | - | 15.833 | evp & chief legal officer |
2023-03-21 | WITTY ANDREW | acquired | - | - | 82.823 | ceo, uhg |
Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Premiums | $ 257,157 | $ 226,233 | $ 201,478 |
Investment and other income | 2,030 | 2,324 | 1,502 |
Total revenues | 324,162 | 287,597 | 257,141 |
Operating costs: | |||
Medical costs | 210,842 | 186,911 | 159,396 |
Operating costs | 47,782 | 42,579 | 41,704 |
Cost of products sold | 33,703 | 31,034 | 30,745 |
Depreciation and amortization | 3,400 | 3,103 | 2,891 |
Total operating costs | 295,727 | 263,627 | 234,736 |
Earnings from operations | 28,435 | 23,970 | 22,405 |
Interest expense | (2,092) | (1,660) | (1,663) |
Earnings before income taxes | 26,343 | 22,310 | 20,742 |
Provision for income taxes | (5,704) | (4,578) | (4,973) |
Net earnings | 20,639 | 17,732 | 15,769 |
Earnings attributable to noncontrolling interests | (519) | (447) | (366) |
Net earnings attributable to UnitedHealth Group common shareholders | $ 20,120 | $ 17,285 | $ 15,403 |
Earnings per share attributable to UnitedHealth Group common shareholders: | |||
Basic | $ 21.47 | $ 18.33 | $ 16.23 |
Diluted | $ 21.18 | $ 18.08 | $ 16.03 |
Basic weighted-average number of common shares outstanding | 937 | 943 | 949 |
Dilutive effect of common share equivalents | 13 | 13 | 12 |
Diluted weighted-average number of common shares outstanding | 950 | 956 | 961 |
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 3 | 1 | 8 |
Products | |||
Revenue from Products and Services | $ 37,424 | $ 34,437 | $ 34,145 |
Services | |||
Revenue from Products and Services | $ 27,551 | $ 24,603 | $ 20,016 |
Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 23,365 | $ 21,375 |
Short-term investments | 4,546 | 2,532 |
Accounts receivable, net of allowances of $877 and $954 | 17,681 | 14,216 |
Other current receivables, net of allowances of $1,433 and $993 | 12,769 | 13,866 |
Assets under management | 4,087 | 4,449 |
Prepaid expenses and other current assets | 6,621 | 5,320 |
Total current assets | 69,069 | 61,758 |
Long-term investments | 43,728 | 43,114 |
Property, equipment and capitalized software, net of accumulated depreciation and amortization of $6,930 and $5,992 | 10,128 | 8,969 |
Goodwill | 93,352 | 75,795 |
Other intangible assets, net of accumulated amortization of $6,137 and $5,636 | 14,401 | 10,044 |
Other assets | 15,027 | 12,526 |
Total assets | 245,705 | 212,206 |
Current liabilities: | ||
Medical costs payable | 29,056 | 24,483 |
Accounts payable and accrued liabilities | 27,715 | 24,643 |
Short-term borrowings and current maturities of long-term debt | 3,110 | 3,620 |
Unearned revenues | 3,075 | 2,571 |
Other current liabilities | 26,281 | 22,975 |
Total current liabilities | 89,237 | 78,292 |
Long-term debt, less current maturities | 54,513 | 42,383 |
Deferred income taxes | 2,769 | 3,265 |
Other liabilities | 12,839 | 11,787 |
Total liabilities | 159,358 | 135,727 |
Commitments and contingencies (Note 12) | ||
Redeemable noncontrolling interests | 4,897 | 1,434 |
Equity: | ||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding | 9 | 10 |
Retained earnings | 86,156 | 77,134 |
Accumulated other comprehensive loss | (8,393) | (5,384) |
Nonredeemable noncontrolling interests | 3,678 | 3,285 |
Total equity | 81,450 | 75,045 |
Total liabilities, redeemable noncontrolling interests and equity | $ 245,705 | $ 212,206 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 934 | 941 |
Common Stock, Shares, Outstanding | 934 | 941 |